Welldoc®, a trailblazer in digital health that is revolutionizing chronic disease management to help transform lives, today announced an expanded leadership team with the appointments of Keith Reynolds as Chief Operating Officer, David Driscoll as Chief Revenue Officer, and Linda Piazza as Senior Vice President of Sales. The additions will support the company’s ongoing strategic partnerships and commercialization efforts for its digital health products for chronic conditions, including its award-winning product for diabetes, BlueStar.
“As data continue to show the value of BlueStar and the demand for impactful digital health offerings increases, we are well-positioned to continue our accelerated growth trajectory. The specialized experiences that Keith, Dave and Linda bring to our commercial team will be key to our success,” said Kevin McRaith, CEO at Welldoc. “Together they bring more than 60 years of leadership in commercializing digital health platforms, payer sales management and business development in the chronic disease space. We are delighted to welcome them to Welldoc and look forward to improving the lives of those living with chronic diseases.”
Prior to joining Welldoc, Keith Reynolds spent 17 years at CVS Health, where he served as Vice President, Enterprise Health Plans and Market Strategy. In this role, he led multi-functional teams including Enterprise Health Plan, Enterprise Market Strategy and the Prescription Affordability program. Prior to that, Keith held leadership roles within CVS Caremark working with Health Plans and new business development. Following CVS Health, Reynolds served as Chief Commercial Officer of Castlight.
“There is a growing demand for innovative digital solutions that improve health outcomes and help lower the total cost of care,” said Keith Reynolds. “The data on the impacts of Welldoc’s platform solutions for chronic disease management are impressive and I am thrilled to help increase the reach of these important tools by launching new collaborations and commercial relationships.”
David Driscoll was most recently Chief Revenue Officer at Streamline Health where he managed business development and product strategy and accelerated new business growth in the revenue integrity space. Previously, as Chief Growth Officer and Senior Vice President of Provider Solutions at American Well (formerly Avizia), he positioned the company as a leading enterprise-wide telehealth solution for large provider organizations. Driscoll has a proven track record of increasing sales and market share while creating well-run business organizations.
“The digital health revolution is making real impacts in care, especially in chronic disease management. Data from Welldoc’s recent real-world, observational study demonstrated strong patient engagement and self-care behaviors and a reduction in ER visits – these are important indicators that demonstrate BlueStar’s potential to impact the chronic care landscape,” said David Driscoll. “I am excited about joining Welldoc. While researching the company, the first thing I learned was that Welldoc customers love BlueStar. Welldoc is uniquely positioned to become the leader in the digital health space for health plans, health systems and employers.”
Prior to joining Welldoc, Linda Piazza spent more than eight years at Kaiser Permanente as National Sales Executive and was responsible for new business development and sales focusing on large national employers. She was a four-time President’s Circle Sales Quota Award winner. Prior to that, she held various sales and business development positions at national health plans and health solutions companies, including CorSolutions, UnitedHealthcare, Blue Cross Blue Shield of North Carolina and Cigna.
“Chronic diseases affect more than 100 million people in the United States and add significant burden to patients and their families. I am proud to be part of the team that is expanding access to Welldoc’s transformative approach for improving, not only the health of an individual, but a population,” said Linda Piazza.
Recently, Welldoc released data showing that engaged BlueStar users with type 2 diabetes experience clinically significant reductions in A1C & blood glucose, reductions in ER visits, reductions in costs, strong engagement and increases in self-care behaviors.
About Welldoc®
Welldoc® is revolutionizing chronic disease management to help transform lives. BlueStar®, an FDA-cleared digital health solution, guides individuals through the complicated journey of living with diabetes by enabling them to self-manage their conditions and enhancing connections to their healthcare team. Welldoc streamlines the relationships between payers, employers and healthcare systems resources, with the goal of improving population health and reducing costs of chronic care. For more information, visit www.welldoc.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200909005302/en/